Results 91 to 100 of about 989,554 (310)

Molecular Simulations of Polymer‐based Drug Nanocarriers: From Physical and Structural Properties to Controlled Release

open access: yesAdvanced Healthcare Materials, EarlyView.
Polymer‐based drug delivery systems can effectively overcome the limitations of free drugs in terms of solubility, stability, and plasma half‐life, yet their development has traditionally relied on time‐consuming trial‐and‐error approaches. This review highlights recent advances in applying molecular simulation to the design of polymer‐based drug ...
Ping Gao   +4 more
wiley   +1 more source

Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy

open access: yesAdvanced Materials, EarlyView.
This work explores the MOF landscape to select a single, optimal candidate for successfully delivering cancer drugs (gemcitabine, paclitaxel, SN‐38) into tough pancreatic tumors. Machine learning and simulations guide this search, demonstrating colloidal stability, excellent biocompatibility, cellular uptake, and sustained release.
Francesca Melle   +9 more
wiley   +1 more source

Bi‐Functional Topospecific Nanoparticles to Promote Immune‐Tumor Cell Engagement as A New Immunotherapeutic Strategy

open access: yesAdvanced Materials, EarlyView.
A Janus‐engineered nanoplatform (J‐pHLIP‐PD1), featuring separate tumor‐ and immune‐targeting faces, bridges melanoma cells and cytotoxic T lymphocytes using toposelective pHLIP and anti‐PD‐1 presentation. This strategy elicits robust antitumor responses, promotes immunogenic tumor cell death, suppresses lung metastasis in vivo, and provides a modular,
Alba Ortuño‐Bernal   +9 more
wiley   +1 more source

Tertiary Care Clinical Experience with Intravenous Lidocaine Infusions for the Treatment of Chronic Pain

open access: yesPain medicine (Malden, Mass.), 2018
E. Iacob   +10 more
semanticscholar   +1 more source

Plaque‐Targeted Delivery of Fluoride‐Free MXene Nanozyme for Alleviating Atherosclerosis via Sonocatalytic Therapy

open access: yesAdvanced Materials, EarlyView.
This work has developed a dual enzyme‐mimicking and ultrasound‐responsive Nb2C‐Pt@HA‐PEG nanozyme. ROS‐eliminating and anti­inflammatory capability of Nb2C‐Pt@HA‐PEG under US irradiation are demonstrated on macrophages and endothelial cells in vitro. Nb2C‐Pt@HA‐PEG‐mediated sonocatalytic therapy exerts an outstanding anti‐atherosclerosis efficacy by ...
Qianqian Bai   +6 more
wiley   +1 more source

Validation of High-Performance Liquid Chromatography for determination and stability assessment of dobutamine hydrochloride in pediatric intravenous therapy

open access: yesEvidência
Severely ill children and newborns typically require a wide range of intravenous medications as part of specific therapies tailored to their developmental and growth characteristics.
Tatiany Calegari   +6 more
doaj  

Harnessing Photo‐Energy Conversion in Nanomaterials for Precision Theranostics

open access: yesAdvanced Materials, EarlyView.
Harnessing photo‐energy conversion in nanomaterials enables precision theranostics through light‐driven mechanisms such as photoluminescence, photothermal, photoelectric, photoacoustic, photo‐triggered surface‐enhanced Raman scattering (SERS), and photodynamic processes. This review explores six fundamental principles of photo‐energy conversion, recent
Jingyu Shi   +4 more
wiley   +1 more source

Engineered Plasmonic and Fluorescent Nanomaterials for Biosensing, Motion, Imaging, and Therapeutic Applications

open access: yesAdvanced Materials, EarlyView.
A schematic illustration of how noble metals can be used to create nanoparticles (NPs) or nanoclusters (NCs). Noble metal NPs, due to their plasmonic properties, enable photothermal therapy and surface‐enhanced Raman scattering (SERS). In contrast, NCs, which lack a plasmonic resonance band, exhibit fluorescence, making them ideal for bioimaging ...
David Esporrín‐Ubieto   +3 more
wiley   +1 more source

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

open access: yesArthritis & Rheumatism, 1998
R. Maini   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy